UBS reiterated a 'Buy' rating on the stock of Elevance Health, Inc. on August 8, 2025.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS reiterated a 'Buy' rating on the stock of Elevance Health, Inc. on August 8, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
Elevance Health, Inc.
American healthcare company
Nothing else this week.
Related events
- UBS analyst maintained a Buy rating on Applied Materials stock.
- UBS, HSBC, and CLSA issued various ratings and price targets for Bajaj Finance Ltd on July 31, 2026.
- UBS analyst suggests 'Buy' rating on Hindustan Unilever Ltd stock.
- UBS analyst upgraded Allegiant Air stock to Buy on September 18, 2026.
- UBS initiated coverage with a 'buy' rating for Persimmon plc.
Coverage
Newest first; wire copies grouped- Insider MonkeyUBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reitera